Standard
The controversy of varicella vaccination in children with acute lymphoblastic leukemia. / Caniza, Miguela A; Hunger, Stephen P; Schrauder, Andre; Valsecchi, Maria Grazia; Pui, Ching-Hon; Masera, Giuseppe; Members of International Study Group of Childhood ALL ( “Ponte di Legno Working Group”) ; Schmiegelow, Kjeld.
I:
Pediatric Blood & Cancer, Bind 58, Nr. 1, 2012, s. 12-6.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Caniza, MA, Hunger, SP, Schrauder, A, Valsecchi, MG, Pui, C-H, Masera, G, Members of International Study Group of Childhood ALL ( “Ponte di Legno Working Group”)
& Schmiegelow, K 2012, '
The controversy of varicella vaccination in children with acute lymphoblastic leukemia',
Pediatric Blood & Cancer, bind 58, nr. 1, s. 12-6.
https://doi.org/10.1002/pbc.22759APA
Caniza, M. A., Hunger, S. P., Schrauder, A., Valsecchi, M. G., Pui, C-H., Masera, G., Members of International Study Group of Childhood ALL ( “Ponte di Legno Working Group”)
, & Schmiegelow, K. (2012).
The controversy of varicella vaccination in children with acute lymphoblastic leukemia.
Pediatric Blood & Cancer,
58(1), 12-6.
https://doi.org/10.1002/pbc.22759Vancouver
Caniza MA, Hunger SP, Schrauder A, Valsecchi MG, Pui C-H, Masera G o.a.
The controversy of varicella vaccination in children with acute lymphoblastic leukemia.
Pediatric Blood & Cancer. 2012;58(1):12-6.
https://doi.org/10.1002/pbc.22759Author
Caniza, Miguela A ; Hunger, Stephen P ; Schrauder, Andre ; Valsecchi, Maria Grazia ; Pui, Ching-Hon ; Masera, Giuseppe ; Members of International Study Group of Childhood ALL ( “Ponte di Legno Working Group”) ; Schmiegelow, Kjeld. / The controversy of varicella vaccination in children with acute lymphoblastic leukemia. I: Pediatric Blood & Cancer. 2012 ; Bind 58, Nr. 1. s. 12-6.
Bibtex
@article{43b182726bca42b49451e8d0be501ac0,
title = "The controversy of varicella vaccination in children with acute lymphoblastic leukemia",
abstract = "The available guidelines for varicella vaccination of susceptible children with acute lymphoblastic leukemia (ALL) have become increasingly conservative. However, vaccination of those who have remained in continuous complete remission for 1 year and are receiving chemotherapy is still considered a reasonable option. There is little available data to allow a comparison of the risk versus benefit of vaccinating these patients.",
author = "Caniza, {Miguela A} and Hunger, {Stephen P} and Andre Schrauder and Valsecchi, {Maria Grazia} and Ching-Hon Pui and Giuseppe Masera and K. Schmiegelow and Kjeld Schmiegelow",
note = "Copyright {\textcopyright} 2010 Wiley Periodicals, Inc.",
year = "2012",
doi = "10.1002/pbc.22759",
language = "English",
volume = "58",
pages = "12--6",
journal = "Pediatric Blood & Cancer",
issn = "1545-5009",
publisher = "JohnWiley & Sons, Inc.",
number = "1",
}
RIS
TY - JOUR
T1 - The controversy of varicella vaccination in children with acute lymphoblastic leukemia
AU - Caniza, Miguela A
AU - Hunger, Stephen P
AU - Schrauder, Andre
AU - Valsecchi, Maria Grazia
AU - Pui, Ching-Hon
AU - Masera, Giuseppe
AU - Members of International Study Group of Childhood ALL ( “Ponte di Legno Working Group”)
AU - Schmiegelow, Kjeld
N1 - Copyright © 2010 Wiley Periodicals, Inc.
PY - 2012
Y1 - 2012
N2 - The available guidelines for varicella vaccination of susceptible children with acute lymphoblastic leukemia (ALL) have become increasingly conservative. However, vaccination of those who have remained in continuous complete remission for 1 year and are receiving chemotherapy is still considered a reasonable option. There is little available data to allow a comparison of the risk versus benefit of vaccinating these patients.
AB - The available guidelines for varicella vaccination of susceptible children with acute lymphoblastic leukemia (ALL) have become increasingly conservative. However, vaccination of those who have remained in continuous complete remission for 1 year and are receiving chemotherapy is still considered a reasonable option. There is little available data to allow a comparison of the risk versus benefit of vaccinating these patients.
U2 - 10.1002/pbc.22759
DO - 10.1002/pbc.22759
M3 - Journal article
VL - 58
SP - 12
EP - 16
JO - Pediatric Blood & Cancer
JF - Pediatric Blood & Cancer
SN - 1545-5009
IS - 1
ER -
